Clinical value of the sTim-3 level in chronic kidney disease

LINGLI CHEN1*, YUAN QIN1*, BO LIN2*, XIAOMEI YU1, SHAOXIONG ZHENG1, XIUMEI ZHOU1, XIAOBIN LIU3, YIGANG WANG1, BIAO HUANG1, XIUMEI ZHOU1 and LIANG WANG3

1College of Life Sciences and Medicine, Zhejiang Sci-Tech University, Hangzhou, Zhejiang 310018; 2Department of Nephrology, Zhejiang Provincial People's Hospital, Hangzhou, Zhejiang 310014; 3Department of Nephrology, Wuxi People's Hospital Affiliated to Nanjing Medical University, Wuxi, Jiangsu 214023; 4Department of Nephrology, The First People's Hospital of Hangzhou Lin'an District, Affiliated Lin'an People's Hospital, Hangzhou Medical College, Hangzhou, Zhejiang 311300, P.R. China

Received February 15, 2022; Accepted June 13, 2022

DOI: 10.3892/etm.2022.11543

Abstract. Chronic kidney disease (CKD) is a global disease that is harder to treat at a later stage. Therefore, early diagnosis and monitoring of CKD are crucial. T cell immunoglobulin and mucin domain molecule 3 (Tim-3) is a negative regulator of the T cell responses and it is involved in the immunomodulation of kidney disease. To date, only a small number of reports regarding serum soluble Tim-3 (sTim-3) in CKD are available. In the present study, the serum levels of sTim-3 in patients with CKD at different stages and the levels of sTim-3 in the early diagnosis and monitoring of CKD were analyzed. A highly sensitive time-resolved fluorescence immunoassay was performed to quantify sTim-3 levels in 318 patients with CKD and 114 healthy individuals. The serum levels of sTim-3 in patients with CKD (33.47±20.77 ng/ml) were significantly higher than those in the healthy individuals group (8.32±3.23 ng/ml; P<0.0001). As CKD progressed from stage G1 to G5, the serum sTim-3 level gradually increased (P<0.0001). A cut-off value of 13.63 ng/ml for the sTim-3 concentration was effective in diagnosing patients with CKD (area under the receiver operating characteristic curve, 0.9176; sensitivity, 79.87%; specificity, 96.49%). At this critical value, the positive detection rate of CKD in the early stages (G1 + G2), G3, G4 and G5 was 55.70, 77.78, 84.44 and 92.86%, respectively. In conclusion, serum sTim-3 had an auxiliary effect that was useful in the early diagnosis of CKD. The positive detection rate of CKD in the early stages was 55.70%, which can assist other clinically common kidney disease indicators.

Introduction

Chronic kidney disease (CKD) is a worldwide disease that affects >10% of the world's population (1). CKD can be caused by several clinical conditions, including renal tubular damage, renal vascular disease, and primary and secondary glomerulonephritis. The progression of CKD can be divided into five stages according to the glomerular filtration rate (GFR) (2). Once CKD progresses to stage 5, it is hard to treat and requires timely initiation of renal replacement therapy (3). Early detection and intervention can markedly reduce CKD-related clinical complications, which may be reflected by improvement of the survival rate. Currently, tissue biopsy is the gold standard in the clinical evaluation of CKD (4). However, the invasiveness of this method can cause discomfort and possibly lead to complications (5). Serum creatinine (CREA) and proteinuria are common serum biomarkers (6) of kidney disease; however, their sensitivity and specificity are limited. In CKD and acute kidney injury, the sensitivity of serum creatinine is only 17% (7) and they have little effect on early detection or monitor disease progression (8). Therefore, more effective serum markers for the early diagnosis and progression monitoring of CKD are required.

The immunomodulatory role of T cell immunoglobulin and mucin domain molecule 3 (Tim-3) in kidney disease has attracted considerable interest. Tim-3 is a member of the TIM family of immunomodulatory proteins and was first found to be
expressed on T helper (Th) 1 cells (9). Mast cells, natural killer cells, dendritic cells, Th17 cells and cytotoxic CD8+ T cells can express Tim-3 (10-14). Tim-3 can be found in two forms: A membrane-bound Tim-3 and a soluble Tim-3 (sTim-3) form (15). Membrane-bound Tim-3 can be cleaved from the cell surface by a disintegrin and metalloproteinase domain-containing protein 10 and 17 to generate sTim-3 (16). It has been reported that Tim-3 expression is increased in the macrophages of diabetic mice, and this increase is positively associated with the severity of renal dysfunction (17). In immune-related nephropathy, Tim-3 is highly expressed in the renal tissues of patients with IgA nephropathy and in the CD14+ monocytes present in the peripheral blood of patients with systemic lupus erythematosus nephropathy (18,19). In nephrotoxic serum nephritis, Tim-3 negatively regulates the activation of renal macrophages. Furthermore, blocking Tim-3 increases the number of infiltrating inflammatory cells in the kidneys, thereby aggravating nephritis. This finding suggests that Tim-3 exerts a protective role in the process of nephritis (20). To the best of our knowledge, studies on the involvement of Tim-3 in kidney diseases have mainly focused on its membrane-bound form (21-23). In the present study, a highly sensitive time-resolved fluorescence immunoassay was used to detect serum sTim-3 levels in patients with CKD. The serum levels of sTim-3 in patients with CKD at different stages and the role of sTim-3 in the early diagnosis and monitoring of CKD were analyzed.

Materials and methods

Reagents and instruments. Two monoclonal antibodies against different epitopes of Tim-3, capture (Cat.No:SEK10390-R024; rabbit McAb) and detection antibody (Cat.No:SEK10390-MM04; mouse MaB), and Tim-3 protein, Human, recombinant (Cat. No:SEK 10390-H08H, His Tag); were purchased from Sino Biological Inc. ProClin 300 (48915-U), Tris-HCl (1082191), Sephadex-G50 (G5080), NaCl (S9888), Na2CO3 (S7795), NaHCO3 (S6014), diethylenetriaminepentaacetic acid (DTPA; S7794), 2-naphthoyltrifluoroacetone (β-NTA; 343633), Triton X-100 (X100P3) and Tween-20 (P9416) were purchased from Sigma-Aldrich; Merck KGaA. BSA (240GR100) was purchased from Guangzhou Saiguo Biotech Co., Ltd.

A time-resolved immunofluorescence analyzer was purchased from Guangzhou Daan Gene Co., Ltd. and 96-well plates were purchased from Xiamen Yunpeng Technology Development Co., Ltd.

Buffer composition. Coating buffer (50 mmol/l Na2CO3-NaHCO3; pH 9.6); elution buffer (50 mmol/l Tris-HCl, 0.2% BSA and 0.05% ProClin 300; pH 7.8); washing buffer (50 mmol/l Tris-HCl, 0.9% NaCl, 0.02% Tween-20 and 0.01% ProClin 300; pH 7.8); blocking solution (50 mmol/l Tris-HCl, 0.9% NaCl, 1% BSA and 0.05% ProClin 300; pH 7.8); labeling buffer (50 mmol/l Na2CO3-NaHCO3; pH 9.0); analysis buffer (50 mmol/l Tris-HCl, 0.9% NaCl, 0.5% BSA, 0.0008% DTPA, 0.0005% Phloxine B, 0.01% Tween-20 and 0.05% ProClin 300; pH 7.8); and enhancement solution (15 µmol/l β-NTA and 50 µmol Triton X-100; pH 3.2).

Serum samples. Serum samples were collected from 318 patients with CKD between June 2020 and December 2021 either at Wuxi People's Hospital (Wuxi, China) or at Zhejiang Provincial People’s Hospital (Hangzhou, China). The inclusion criteria were: i) Age >18 years; and ii) presence of CKD, which was defined as estimated GFR (eGFR) <90 ml/min/1.73 m2. The exclusion criteria were: i) Kidney transplantation; and ii) renal dialysis with acute kidney injury (AKI).

According to the CKD staging standard proposed by the Kidney Disease Prognosis Quality Initiative Working Group of the American Kidney Disease Foundation in 1999 (24), the patients were divided into five groups according to their eGFR (G1, eGFR ≥90 ml/min/1.73 m2; G2, 89 ml/min/1.73 m2 ≥eGFR ≥60 ml/min/1.73 m2; G3, 59 ml/min/1.73 m2 ≥eGFR ≥30 ml/min/1.73 m2; G4, 30 ml/min/1.73 m2 ≥eGFR ≥15 ml/min/1.73 m2; and G5, eGFR <15 ml/min/1.73 m2). The number of samples from different stages was random. In addition, serum samples were collected from 114 healthy individuals between June 2020 and December 2021 at Wuxi People’s Hospital (Wuxi, China). Demographic characteristics are listed in Table I. The inclusion criteria for the control group were: i) Hospital admission for general physical examination; ii) no history of kidney disease; and iii) eGFR ≥90 ml/min/1.73 m2. The exclusion criteria for the control group were as follows: i) History of kidney disease; ii) eGFR ≥90 ml/min/1.73 m2; and iii) have kidney disease or other disease.

Venous blood (5 ml) was collected from each participant and centrifuged at 1,000 g for 10 min at 2-6°C. The supernatant (serum) was stored at -80°C.

Blood test results for CREA, eGFR, albumin (ALB), uric acid and urea levels were provided by the hospital. CREA, ALB, URIC and Urea were determined by biochemical analyzer (Beckman coulter AU). eGFR is obtained as follows: Male eGFR=(140-age)xweight(kg)x1.23/CREA (umol/l); female eGFR=(140-age)xweight(kg)x1.03/CREA (umol/l).

The study was approved by the Ethics Committee of the Wuxi People's Hospital Affiliated to Nanjing Medical University (NMU2018211, Wuxi, China) and Ethics Committee of the Zhejiang Provincial People's Hospital (2018KT063, Zhejiang, China). Written informed consent was obtained from all registered participants.

Time-resolved fluorescence immunoassay double antibody sandwich method for serum sTim-3 detection. The experimental protocol has been described previously (25). Briefly, the steps were as follows: Antibody coating. The capture antibody was diluted to 2 µg/ml with a coating buffer (dilution, 1:500), and 100 µl of the diluted capture antibody solution was added to each well of the 96-well plate. The solutions were incubated overnight at 4°C. The plate was washed once with washing buffer, and 150 µl blocking solution was added to each well. After blocking at room temperature for 2 h, the blocking solution was discarded. After drying, the antibody-coated plate was stored at -20°C until use.

Labeling antibody. The detection antibody (300 µg) was added to an ultrafiltration tube. Through ultrafiltration, the buffer of the antibody to be detected was converted into a labeling buffer with pH 9.0. The collected antibody was mixed with 30 µl 2 mg/ml diethylenetriaminepentaacetic acid-Eu3+, and the mixture was incubated at 30°C overnight. The next day, the labeled antibody was purified with Sephadex G50 and elution...
buffer. Finally, the Eu³⁺-McAb-labeled antibody was collected and stored at -20°C.

*sTim-3 antigen dilution.* sTim-3 antigen was diluted with an analysis buffer to different concentrations (6.25, 12.5, 25, 50 and 100 ng/ml).

**Determination of sTim-3 concentration in serum.** The standard solution or serum sample (100 µl) was added into a 96-well microtiter plate coated with the anti-Tim-3 capture antibody. The plate was incubated at 37°C for 1 h with shaking and washed twice with washing buffer (room temperature and 5 sec each). Subsequently, 100 µl Eu³⁺-McAb (diluted 1:1,000 with analysis buffer) was added to each well, incubated at 37°C for 1 h, and then washed six times with washing buffer. Furthermore, ~100 µl enhancement solution was added to each well, and the plate was incubated with shaking for 3 min at 37°C. Finally, fluorescence was analyzed using the time-resolved immunofluorescence analyzer (Guangzhou Daan Gene Co., Ltd., Guangzhou, China).

**Statistical analysis.** Data are presented as the mean ± standard deviation or quartile differences. Statistical analysis was performed using SPSS software version 21.0 (IBM Corp.). Unpaired Student's t-test was performed to compare the levels of serum indicators in patients and controls. One-way ANOVA and a post hoc test (Tamhane's T2) for multiple comparisons were used to analyze the differences among groups. sTim-3 and various clinical parameters in CKD stages defined by eGFR interval were compared using the Jonckheere-Terpstra test. The correlations among the values were determined by calculating Spearman's correlation coefficient. GraphPad Prism 7.0 (GraphPad Software, Inc.) was used to draw the

**Table I. Comparison of various parameters in the different GFR stages of chronic kidney disease.**

| Index               | Control     | G1   | G2   | G3   | G4   | G5   | P-value |
|---------------------|-------------|------|------|------|------|------|---------|
| Sex, n (M/F)        | 55/59       | 20/24| 17/18| 24/30| 23/22| 69/71| 0.2700  |
| Age, years          | 53.12±15.02 | 45.31±14.14 | 53.16±15.76 | 65.98±17.32 | 64.1±17.07 | 59.89±17.16 | 0.0020  |
| eGFR, ml/min/1.73 m²| 120.80±13.56| 104.60±10.81 | 76.93±8.18  | 41.56±6.95  | 20.57±4.51 | 7.26±3.11 | <0.0001 |
| Urea, mmol/l        | 4.90±1.55   | 9.45±9.94 | 9.93±14.74 | 9.66±4.09 | 15.88±8.31 | 22.24±9.16 | <0.0001 |
| CREA, µmol/l        | 85.81±15.12 | 164.94±261.61 | 88.53±21.27 | 143.61±45.46 | 229.30±81.28 | 655.39±290.41 | <0.0001 |
| ALB, g/l            | 44.89±7.32  | 35.78±8.36 | 41.66±33.84 | 31.63±7.64 | 31.43±6.67 | 7.26±3.11 | 0.0940  |
| URIC, µmol/l        | 363.83±40.66| 391.70±129.29 | 356.50±126.77 | 332.03±132.12 | 382.65±155.62 | 366.91±122.98 | 0.8030  |
| Urea/CREA           | 0.06±0.02   | 0.08±0.03 | 0.08±0.04 | 0.07±0.03 | 0.10±0.19 | 0.04±0.02 | <0.0001 |
| sTim-3, ng/ml       | 8.32±3.23   | 20.28±19.99 | 24.74±20.43 | 29.10±17.33 | 35.06±20.47 | 40.97±17.80 | <0.0001 |

Age, eGFR, Urea, CREA, ALB, URIC, Urea and sTim-3 are presented as the mean ± SD. The sTim-3 concentration and various clinical parameters in different GFR stages were analyzed using the Jonckheere-Terpstra test. P<0.05 was considered to indicate a statistically significant difference. ALB, albumin; CREA, serum creatinine; eGFR, estimated glomerular filtration rate; F, female; M, male; sTim-3, soluble T cell immunoglobulin and mucin domain molecule 3; URIC, uric acid.
CHEN et al: CLINICAL VALUE OF THE sTim-3 LEVEL IN CKD

receiver operating characteristic curve for the determination of the best cut-off value of serum sTim-3, as well as for the evaluation of the performance of sTim-3 in differentiating patients with CKD from the healthy control group. P<0.05 was considered to indicate a statistically significant difference.

Results

Differences between the serum sTim-3 levels of healthy controls and patients with CKD. As shown in Fig. 1, the serum sTim-3 concentrations of patients with CKD (33.47±20.77 ng/ml) were significantly higher than those of healthy controls (8.32±3.23 ng/ml; P<0.0001).

Figure 3. ROC analysis of serum sTim-3 suggests that this has diagnostic value for healthy controls and patients with CKD. (A) ROC curve of serum sTim-3 in healthy controls and patients with CKD (G1). (B) ROC curve of serum sTim-3 in healthy controls and patients with CKD (G2). (C) ROC curve of serum sTim-3 in healthy controls and patients with CKD (G3). (D) ROC curve of serum sTim-3 in healthy controls and patients with CKD (G4). (E) ROC curve of serum sTim-3 in healthy controls and patients with CKD (G5). (F) ROC curve of serum sTim-3 in healthy controls and patients with CKD (G1-G5). ROC, receiver operating characteristic; sTim-3, soluble T cell immunoglobulin and mucin domain molecule 3; CKD, chronic kidney disease; AUC, area under the curve.

Relationship between sTim-3 levels and other clinical indicators in the serum and the stages of CKD. To explore the relationship between serum sTim-3 and the progression of CKD, patients with CKD were divided into five groups according to their disease stage (G1-G5). The Jonckheere-Terpstra test was used to compare sTim-3 levels and changes in various clinical parameters at different GFR stages. The results are shown in Table I. As the disease stage progressed, sTim-3 (P<0.0001), urea (P<0.0001) and CREA (P<0.0001) showed upward trends, whereas urea/CREA (P<0.0001) showed a downward trend. As shown in Fig. 2, the serum sTim-3 concentration gradually increased from the healthy control group to the G5 stage. sTim-3 concentrations of patients with G3 stage

Table II. Multivariate regression analysis of sTim3 and other clinical indicators in patients with chronic kidney disease.

| Clinical indicator | P-value | OR   | 95% CI       |
|--------------------|---------|------|--------------|
| Sex                | 0.124   | 0.313| 0.071-1.374  |
| Age                | 0.009   | 0.930| 0.881-0.982  |
| eGFR               | <0.001  | 0.866| 0.806-0.931  |
| Urea               | 0.286   | 1.428| 0.742-2.749  |
| CREA               | 0.990   | 1.000| 0.988-1.012  |
| ALB                | 0.014   | 0.866| 0.772-0.971  |
| URIC               | 0.496   | 1.002| 0.995-1.010  |
| sTim3              | 0.030   | 1.144| 1.013-1.292  |

OR, odds ratio; eGFR, estimated glomerular filtration rate; CREA, serum creatinine; ALB, albumin; URIC, uric acid; sTim3, soluble T cell immunoglobulin and mucin domain molecule 3.
were significantly higher than those of G1 (P<0.05); sTim-3 concentrations of patients with G4 stage were significantly higher than those of G2 (P<0.001); sTim-3 concentrations of patients with G5 stage were significantly higher than those of G3 (P<0.0001); sTim-3 concentrations of patients with G5 stage were significantly higher than those of G4 (P<0.05).

Multivariate regression analysis of the sTim3 levels and other clinical indicators for patients with CKD. The multivariate regression analysis performed on the sTim‑3 levels in patients with CKD (total) and other clinical indicators (shown in Table II) suggested that eGFR [odds ratio (OR), 0.866; 95% CI, 0.806‑0.931], ALB (OR, 0.866; 95% CI, 0.772‑0.971); age (OR, 0.930; 95% CI, 0.881‑0.982) and sTim-3 (OR, 1.144; 95% CI, 1.013‑1.292) could be independent factors (P<0.05).

Levels of serum sTim‑3 in the early diagnosis of CKD. A receiver operating characteristic curve was drawn and used to evaluate the diagnostic value of serum sTim‑3 in patients with CKD, especially its value in terms of early diagnosis. The results are shown in Fig. 3. From G1 to G5, the area under the curve gradually increased (0.7580, 0.8343, 0.9232, 0.9507 and 0.9758, respectively, from G1 to G5). As CKD developed, the diagnostic value of sTim-3 increased. This further suggests that the concentration of serum sTim-3 is closely related to the development of CKD.

In the diagnosis of CKD, the G1‑G5 stages were diagnosed (Table III) with the use of serum sTim-3 levels. According to the Youden index shown in Fig. 3F, the cut-off value was 13.63 ng/ml. The positive detection rate of early CKD (G1 and G2) was 55.70%. The positive rate in the normal control group was 3.51%.

Correlation between serum sTim‑3 levels and other biochemical indicators. A correlation diagram was generated to explore the correlation between serum sTim-3 and the other clinical indicators of CKD. As shown in Fig. 4, the serum sTim-3 concentrations of the patients with CKD were significantly positively correlated with urea (ρ=0.2005; P=0.0003) and CREA (ρ=0.3148; P<0.0001). Significant negative correlations with eGFR (ρ=-0.3736; P<0.0001), ALB (ρ=-0.1429; P=0.0144) and urea/CREA (ρ=-0.2758; P<0.0001) were observed. There is no significant correlation between serum sTim-3 and URIC (ρ=-0.0534; P=0.3493).

Discussion

CKD is defined as ‘abnormal structure or function of the kidney, lasting >3 months, with health effects’ (26). Given that the early symptoms of CKD are not obvious, its prevention and early diagnosis remain challenging. Currently, the GFR is the best indicator...
for evaluating renal function. The urine isotope collection method is the ‘gold standard’ for measuring GFR. However, this method is time-consuming, expensive and is usually estimated using the formula for an endogenous filtration marker (CREA) (27); therefore, this method has limited value in the early diagnosis of CKD. Therefore, the present study explored novel serum markers, aiming to improve the early diagnosis of CKD.

Tim-3 is an immune checkpoint molecule (9), serving an immunomodulatory role in a variety of diseases, such as viral infections (28,29), systemic lupus erythematosus (30) and tumors (31). However, the clinical value of serum sTim-3 in CKD remains unclear. In the present study, the serum levels of sTim-3 in patients with CKD were quantified and the clinical value of sTim-3 in CKD was explored. The results of the present study demonstrated that sTim-3 levels in the sera of patients with CKD were significantly higher than those in the sera of healthy people. The serum sTim-3 levels increased with the progression of CKD, suggesting that serum sTim-3 could be used to monitor the progression of CKD.

Inflammation serves an important role in the progression of CKD, and circulating monocytes and endothelial cells are the main sources of inflammatory cytokines (32). Tim-3 can negatively regulate the production of anti-inflammatory factors such as IL-10 and proinflammatory factors (TNF-α and IL-6) (33). Therefore, Tim-3 could be involved in CKD by regulating inflammation.

AKI can also lead to the development of CKD (34). An early feature of AKI is that immune cells accumulate in the kidney, and immune cells cause further damage through inflammatory mechanisms (35). The downregulation of Tim-3 impairs the function of regulatory T (Treg) cells in AKI (36). Therefore, Tim-3 may also affect AKI by regulating Treg cells and further participate in the progression of CKD. In addition, the imbalance between Th1 and Th2 could have a central role in the pathogenesis of immune-related nephropathy (30). The combination of Tim-3 and its ligand galectin 9 promotes Treg activation and increases the expression level of Tim-3 proteins during activation. The increase in Tim-3 levels can induce Th1 cell apoptosis, inhibit Th1-type immune responses (37) and promote the shift of the Th1/Th2 balance towards Th2 (38), thereby participating in the development of nephropathy. The level of serum sTim-3 may reflect the level of membrane-bound Tim-3 (12). Therefore, the aforementioned factors may explain why serum sTim-3 levels gradually increased with CKD stage.

Currently, eGFR is the best indicator for measuring renal function (8), while CREA is the most commonly used biomarker of renal function, as it can be used to estimate GFRs (8). Given that the daily production and excretion of CREA are relatively constant, an increase in the CREA level indicates a decrease in the GFR (39). In general, the severity of CKD increases with CREA. Due to continuous damage to the kidneys, the function of excreting wastes is reduced, which causes the accumulation of toxins, including CREA, in the body, resulting in an increase in the urea levels (40). The present study demonstrated that the level of serum sTim-3 in patients with CKD was significantly correlated with eGFR, CREA and urea indicators, suggesting that serum sTim-3 could be used to evaluate the degree of kidney damage and CKD progression. In addition, serum sTim-3 can be effective in the diagnosis of CKD and showed a sensitivity of 79.87% and specificity of 96.49%. The cut-off value of serum sTim-3 was 13.63 ng/ml, and the positive diagnosis rate for CKD in the G1 and G2 stages was 55.70%. The diagnostic eGFR criteria for the G1 stage of CKD and for healthy controls are both ≥90 ml/min/1.73 m², making it difficult to diagnose the early stage of CKD. The present study suggests that serum sTim-3 can be employed in the early diagnosis of CKD.

In summary, the present study revealed that the serum sTim-3 level was a useful clinical reference value for the diagnosis of CKD, especially in the early diagnosis of the disease and in the evaluation of its development, thus providing novel insights into the role of serum sTim-3 in kidney diseases. The present study demonstrated that serum sTim-3 levels were closely related to renal function indicators (eGFR and CREA). The concentrations of sTim-3 in the sera of patients with CKD were higher than those in the sera of healthy individuals. As the stage of CKD increased as the course of the disease worsened, sTim-3 concentrations gradually increased, thereby allowing monitoring of CKD progression. In addition, the quantitative determination of serum sTim-3 may improve the early diagnosis of CKD.

Acknowledgements

Not applicable.

Funding

The present study was supported by the Social Development Fund of Zhejiang Province (grant no. LGF20H200008), Key Research and Development Project of Zhejiang Province (grant no. 2020C03066), National Natural Science Foundation of China (grant no. 82172336), Key Project of Scientific Research Foundation of Chinese Medicine (grant no. 2022ZZ002), Key Research and Development Project of Zhejiang Province (grant no. 2022C03118), and Key Research and Development Project of Hangzhou (grant no. 202004A23).

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions

LC, YQ, BH, XY, BL and SZ wrote the manuscript and analyzed data. BH, XZ, YW, JJ, LW and XL designed and performed the experiments. BH, JJ and LW confirm the authenticity of the raw data. BH, XZ, YW, JJ, LW and XL designed and performed the experiments. BH, JJ and LW confirm the authenticity of all the raw data. All authors have read and approved the final manuscript.

Ethics approval and consent to participate

The present study was conducted in accordance with The Code of Ethics of the World Medical Association (Declaration of Helsinki). This manuscript is part of a study that was approved by the Institutional Research Ethics Committee of the Wuxi People’s Hospital Affiliated to Nanjing Medical University (approval no. NMU2018211; Wuxi, China) and the Zhejiang Provincial People’s Hospital (approval no. 2018KT063; Hangzhou, China), and written informed consent was obtained from all participants.
Patient consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

References
1. Jiang K, Ferguson CM and Lerman LO: Noninvasive assessment of renal fibrosis by magnetic resonance imaging and ultrasound techniques. Transl Res 209: 105‑120, 2019.
2. Liapi D, Sfiridakis A, Livadiotaki A, Alegakis A, Stylianou K, Manika I, Daphnis E and Alexandrakis M: Role of inherited thrombophilia risk factors in patients with CKD‑5 receiving haemodialysis. Acta Haematol 144: 190‑201, 2021.
3. Karam VH, Gasquet I, Delvart V, Hiesse C, Dorent R, Danet C, Samuel D, Charpentier B, Gandjbakhch I, Bismuthand H and Castaing C: Quality of life in adult survivors beyond 10 years after liver, kidney, and heart transplantation. Transplantation 76: 1699‑1704, 2003.
4. Jha V, Garcia‑Garcia G, Iseki K, Li Z, Naicker S, Plattner B, Saran R, Wang AY and Yang CW: Chronic kidney disease: Global dimension and perspectives. Lancet 382: 260‑272, 2013.
5. Luciano RL and Moeckel GW: Update on the native kidney biopsy: Core curriculum. Am J Kidney Dis 73: 404‑415, 2019.
6. Pasala S and Carmody JB: How to use... serum creatinine, cystatin C and GFR. Arch Dis Child Educ Pract Ed 102: 37‑43, 2017.
7. Yerramilli M, Farace G, Quinn J and Yerramilli M: Kidney disease and the nexus of chronic kidney disease and acute kidney injury: The role of novel biomarkers as early and accurate diagnostics. Vet Clin North Am Small Anim Pract 46: 961‑993, 2016.
8. Guzzi F, Cirillo L, Buti E, Becherucci F, Errichelli C, Roberto RM, Buonaguro FP: Urinary biomarkers for diagnosis and prediction of acute kidney allograft rejection: A systematic review. Int J Mol Sci 21: 6889, 2020.
9. Monney L, Sabatos CA, Galgia JL, Ryu A, Waldner H, Chernova T, Manning S, Greenfield EA, Coyle JA, Sobel RA, et al.: Th1‑specific cell surface protein Tim‑3 regulates macrophage activation and severity of an autoimmune disease. Nature 415: 536‑541, 2002.
10. Nakae S, Ikukura Y, Suto H, Akiba H, Umetu DT, Dekruyff RH, Saito H and Galli SJ: TIM‑1 and TIM‑3 enhancement of Th2 cytokine production by mast cells. Blood 110: 2565‑2568, 2007.
11. Ju Y, Hou N, Meng J, Wang X, Zhang X, Zhao D, Liu Y, Zhu F, Zhang L, Sun W, et al.: T cell immunoglobulin‑ and mucin‑domain‑containing molecule‑3 (Tim‑3) mediates natural killer cell suppression in chronic hepatitis B. J Hepatol 52: 623‑630, 2010.
12. Nagabara K, Arikawa T, Oomizu S, Kontani K, Nobumoto A, Tateno H, Watanabe K, Niki T, Katoh S, Miyake M, et al.: Galectin‑9 increases Tim‑3‑dendritic cells and CD8+ T cells and enhances antitumor immunity via galecin‑9‑Tim‑3 interactions. J Immunol 181: 7660‑7669, 2008.
13. Nakae S, Iwakura Y, Suto H and Galli SJ: Phenotypic differences between Th1 and Th17 cells and negative regulation of Th1 cell differentiation by IL‑17. J Leukoc Biol 81: 765‑774, 2007.
14. Wang F, He W, Zhou H, Yuan J, Wu K, Xu L and Chen ZK: The Tim‑3 ligand galectin‑9 negatively regulates CD8+ alloreactive T cell and prolongs survival of skin graft. Cell Immunol 250: 69‑74, 2008.
15. Li F, Li N, Sang J, Fan X, Deng H, Zhang X, Han Q, Lv Y and Liu Z: Highly elevated soluble Tim‑3 levels correlate with increased hepatocellular carcinoma risk and poor survival of hepatocellular carcinoma patients in chronic hepatitis B virus infection. Cancer Manag Res 10: 941‑951, 2018.
16. Geng H, Zhang GM, Li D, Zhang H, Yuan Y, Zhu HG, Xiao H, Hang LF and Feng H: Soluble form of T cell Ig mucin 3 is an inhibitory molecule in T cell‑mediated immune response. J Immunol 176: 1411‑1420, 2006.
17. Huirin Y, Tingting X, Denglen L, Xionghong D, Tixiao W, Chunyang L, Xiaoqia S, Leiqi X, Fan Y, Xiaohong L, et al.: Tim‑3 aggravates podocyte injury in diabetic nephropathy by promoting macrophage activation via the NF‑κB/TNF‑α pathway. Mol Metab 23: 24‑36, 2019.
18. Xiangdong Y, Zhao H, Xiyuan J, Junhui Z, Xuewei Z and Tao P: Expression of human T cell immunoglobulin domain and mucin‑3 on kidney tissue from immunoglobulin A nephropathy patients. Immunol Res 85: 83‑90, 2014.
19. Zhao D, Guo M, Liu B, Lin Q, Xie T, Zhang Q, Jia XX, Shu Q, Liang XH, Gao LF and Ma C: Frontline science: Tim‑3‑mediated dysfunctional engulfment of apoptotic cells in SLE. J Leukoc Biol 102: 1313‑1322, 2017.
20. Schroll A, Eller K, Haber JM, Theurl IM, Wolf AM, Weiss G and Rosenkranz AR: TIM‑3 is upregulated and protective in nephrotic syndrome. Am J Pathol 176: 1716‑1724, 2010.
21. Guo Y, Zhang J, Lai X, Chen M and Guo Y: Tim‑3 exacerbates kidney ischaemia/reperfusion injury through the TLR‑4/NF‑κB signalling pathway and an NLR‑C4 inflammasome activation. Cell Exp Immunol 193: 113‑129, 2018.
22. Cai XZ, Liu N, Qiao Y, Du SY, Chen Y and Chen D: Decreased TIM‑3 mRNA expression in peripheral blood mononuclear cells from nephropathy patients. Genet Mol Res 14: 6543‑6548, 2015.
23. Xie JH, Zhu RR, Zhao L, Zhong YC and Zeng QT: Down‑regulation and clinical implication of galecin‑9 levels in patients with acute coronary syndrome and chronic kidney disease. Curr Med Sci 40: 662‑670, 2020.
24. Kramer H: The national kidney foundation’s kidney disease outcomes quality initiative (KDOQI) grant initiative: Moving clinical practice forward. Am J Kidney Dis 51: 411‑414, 2010.
25. Chen M, Wang L, Wang H, Huang Y, Zhou X, Liu X, Chen H, Huang B and Hu Z: Soluble Tim3 detection by time‑resolved fluorescence immunoassay and its application in membranous nephropathy. J Clin Lab Anal 34: e23428, 2020.
26. Donohoe G, Clarke S, Morris D, Nangle JM, Schwaiger S, Grill M, Corrin A and Robertson IH: Are deficits in executive‑sub processes simply reflecting more general cognitive decline in schizophrenia? Schizophr Res 85: 165‑173, 2006.
27. Wasung ME, Chawla LS and Madero M: Biomarkers of renal function, which and when? Clin Chim Acta 438: 350‑357, 2015.
28. Hakim MS, Jariath R, Spaan M and Boonstra A: Interleukin 15 upregulates the expression of PD‑1 and TIM‑3 on CD4+ and CD8+ T cells. Am J Clin Exp Immunol 9: 10‑21, 2020.
29. Zhang W, Zhang Y, He Y, Wang X and Fang Q: Lipopolysaccharide mediates time‑dependent macrophage M1/M2 polarization through the Tim‑3‑Galecin‑9 signalling pathway. Exp Cell Res 376: 124‑132, 2019.
30. Guo L, Yang X, Xia Q, Zhen J, Zhuang X and Peng T: Expression of human T cell immunoglobulin domain and mucin‑3 (TIM‑3) on kidney tissue from systemic lupus erythematosus (SLE) patients. Clin Exp Med 14: 383‑388, 2014.
31. Acharya N, Sabatos‑Peyton C and Anderson AC: TIM‑3 finds its place in the cancer immunotherapy landscape. J Immunother Cancer 8: e000911, 2020.
32. Mihai S, Codrici E, Popescu ID, Enciu AM, Albulescu L, Necula LG, Mambet C, Anton G and Tanase C: Inflammation‑related mechanisms in chronic kidney disease: prediction, progression, and outcome. J Immunol Res 2018: 2180373, 2018.
33. Lin M, Huang J, Chen WC, Fan ZN and Qin X: The immunomodulatory effects and mechanisms of Tim‑3 action in the early stage of mice with severe acute pancreatitis. Iran J Immunol 17: 52‑63, 2020.
34. Chawla LS, Eggers PW, Star RA and Kimmel PL: Acute kidney injury and chronic kidney disease as interconnected syndromes. N Engl J Med 371: 58‑66, 2014.
35. Ruiz‑Orteaga M, Rayego‑Mateos S, Lamas S, Ortiz A and Rodriguez‑Diez RR: Targeting the progression of chronic kidney disease. Nat Rev Nephrol 16: 269‑288, 2020.
36. Dong Q, Cai C, Gao F, Chen P, Gong W and Shen M: Defective Treg response in acute kidney injury was caused by a reduction in TIM‑3‑Treg cells. Immunol Invest 48: 27‑38, 2019.
37. Guo L, Anderson AC, Schubert A, Xiong H, Imotila J, Khoury SJ, Zheng XX, Strom TB and Kuchroo VK: The Tim‑3 ligand galectin‑9 negatively regulates T helper type 1 immunity. Nat Med 6: 1245‑1252, 2005.
38. Anderson AC: Tim‑3, a negative regulator of anti‑tumor immunity. Curr Opin Immunol 24: 213‑216, 2012.
39. Kashani K, Rosner MH and Ostermann M: Creatinine: From physiology to clinical application. Eur J Intern Med 72: 9‑14, 2020.
40. Post A, Tsikas D and Bakker S: Creatine is a conditionally essential nutrient in chronic kidney disease: A hypothesis and narrative literature review. Nutrients 11: 1044, 2019.